{
    "2019-10-11": [
        [
            {
                "time": "2019-10-10",
                "original_text": "Lilly's REYVOWâ„¢ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval",
                "features": {
                    "keywords": [
                        "REYVOW",
                        "lasmiditan",
                        "FDA Approval",
                        "Migraine"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-10-10",
                "original_text": "UPDATE 1-Eli Lilly's migraine treatment wins U.S. FDA approval",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "migraine",
                        "FDA approval"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-10-10",
                "original_text": "Eli Lilly's migraine treatment wins U.S. FDA approval",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "migraine",
                        "FDA approval"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-10-10",
                "original_text": "Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals",
                "features": {
                    "keywords": [
                        "NVS",
                        "Eye Drug",
                        "FDA Nod",
                        "NVO",
                        "GSK",
                        "PFE"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-10-10",
                "original_text": "Gilead-Galapagos Report Efficacy & Safety Results on RA Drug",
                "features": {
                    "keywords": [
                        "Gilead",
                        "Galapagos",
                        "RA Drug",
                        "Efficacy",
                        "Safety"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-10-10",
                "original_text": "The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout",
                "features": {
                    "keywords": [
                        "Therapix",
                        "Merger Deadline",
                        "Five Prime",
                        "Restructures",
                        "Gilead-Galapagos",
                        "Rheumatism Drug"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "mixed"
                }
            }
        ]
    ]
}